Syndax Pharmaceuticals (SNDX) Income from Continuing Operations (2015 - 2026)
Syndax Pharmaceuticals (SNDX) posted quarterly Income from Continuing Operations of 42441000.0 for Q1 2026, up 49.82% year-over-year from 28328388.6 in Q1 2025, and down 24.73% quarter-over-quarter from 34026000.0 in Q4 2025.
Powered by 
Analysis
Syndax Pharmaceuticals (SNDX) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Syndax Pharmaceuticals' Income from Continuing Operations history runs 12 years deep, the most recent figure standing at 42441000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 49.82% year-over-year to 42441000.0; the TTM figure through Mar 2026 stood at 212671000.0 (up 37.07% YoY), while the FY2025 annual figure was 307235000.0, up 46.31% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 42441000.0, down from 34026000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 34026000.0 in Q4 2025, with the low at 94134000.0 in Q4 2024.
- The 5-year median for Income from Continuing Operations is 51465000.0 (2023), against an average of 57912411.76.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations slumped 136.24% in 2022, then soared 63.85% in 2025.
- Syndax Pharmaceuticals' Income from Continuing Operations stood at 34552000.0 in 2022, then sank by 65.42% to 57156000.0 in 2023, then sank by 64.7% to 94134000.0 in 2024, then jumped by 63.85% to 34026000.0 in 2025, then dropped by 24.73% to 42441000.0 in 2026.
- Business Quant data shows SNDX's Income from Continuing Operations at 42441000.0 in Q1 2026, 34026000.0 in Q4 2025, and 60457000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Syndax Pharmaceuticals | 1.83 Bn | 1.28 Bn | 60.67 Mn | -36.25 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -36.25 Mn |
| Mar 31, 2026 | -34.64 Mn |
| Dec 31, 2025 | -58.22 Mn |
| Sep 30, 2025 | -52.16 Mn |
| Jun 30, 2025 | -63.41 Mn |
| Mar 31, 2025 | -83.40 Mn |
| Dec 31, 2024 | -89.13 Mn |
| Sep 30, 2024 | -84.16 Mn |
| Jun 30, 2024 | -74.36 Mn |
| Mar 31, 2024 | -80.58 Mn |
| Dec 31, 2023 | -72.42 Mn |
| Sep 30, 2023 | -51.08 Mn |
| Jun 30, 2023 | -49.95 Mn |
| Mar 31, 2023 | -45.59 Mn |
| Dec 31, 2022 | -39.09 Mn |
| Sep 30, 2022 | -35.11 Mn |
| Jun 30, 2022 | -39.11 Mn |
| Mar 31, 2022 | -38.19 Mn |
| Dec 31, 2021 | 95.85 Mn |
| Sep 30, 2021 | -20.60 Mn |